Zurcher Kantonalbank Zurich Cantonalbank Buys 168,975 Shares of Moderna, Inc. (NASDAQ:MRNA)

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 107.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 326,749 shares of the company’s stock after acquiring an additional 168,975 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.08% of Moderna worth $13,586,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB increased its position in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the last quarter. Venturi Wealth Management LLC grew its stake in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after buying an additional 664 shares in the last quarter. Compass Planning Associates Inc acquired a new position in Moderna during the fourth quarter worth $37,000. Larson Financial Group LLC raised its position in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after acquiring an additional 317 shares in the last quarter. Finally, Rakuten Securities Inc. lifted its stake in Moderna by 477.3% in the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after acquiring an additional 778 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Up 3.7 %

NASDAQ MRNA opened at $35.01 on Thursday. The firm has a 50-day moving average price of $36.25 and a two-hundred day moving average price of $48.01. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47. The company has a market capitalization of $13.51 billion, a P/E ratio of -3.77 and a beta of 1.86.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on MRNA shares. UBS Group lowered their price objective on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Wolfe Research began coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target for the company. The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Argus cut Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $40.00 target price on shares of Moderna in a report on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $60.63.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.